Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE PRESERVATIVE FREE versus NEOSTIGMINE METHYLSULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE PRESERVATIVE FREE versus NEOSTIGMINE METHYLSULFATE.
EDROPHONIUM CHLORIDE PRESERVATIVE FREE vs NEOSTIGMINE METHYLSULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging the action of acetylcholine at nicotinic and muscarinic receptors, enhancing neuromuscular transmission.
Inhibits acetylcholinesterase at the neuromuscular junction, increasing acetylcholine availability and enhancing cholinergic transmission.
2 mg intravenous (IV) or intramuscular (IM) as a test dose; for myasthenia gravis diagnosis: 2 mg IV test dose followed by 8 mg IV after 30 seconds if no reaction; for myasthenic crisis: 2 mg IV; for reversal of nondepolarizing neuromuscular blockade: 0.5-1 mg/kg IV.
0.5-2.5 mg intravenously or intramuscularly every 2-4 hours as needed for reversal of neuromuscular blockade or treatment of myasthenia gravis; for reversal of non-depolarizing neuromuscular blockade, 0.03-0.07 mg/kg intravenously with anticholinergic.
None Documented
None Documented
Terminal elimination half-life is 1-2 hours in healthy adults; prolonged up to 4-6 hours in renal impairment.
Terminal elimination half-life is approximately 0.7 to 1.2 hours (mean 0.8 h) in healthy adults. In renal impairment, half-life may be prolonged up to 3-4 hours, requiring dose adjustment.
Primarily renal excretion of unchanged drug (approximately 70-80%) with minor biliary excretion (10-15%).
Renal excretion of unchanged drug accounts for approximately 50% of elimination; the remainder is metabolized by microsomal enzymes and excreted in urine as metabolites. Biliary/fecal elimination is minimal (<5%).
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor